Literature DB >> 18842393

Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years.

Martin Lambert1, Benno G Schimmelmann, Alexander Schacht, Anne Karow, Thomas Wagner, Peter M Wehmeier, Christian G Huber, Hans-Peter Hundemer, Ralf W Dittmann, Dieter Naber.   

Abstract

OBJECTIVE: To study the longitudinal patterns of subjective wellbeing in schizophrenia using cluster analysis and their relation to recovery criteria, further to examine predictors for cluster affiliation, and to evaluate the sensitivity and specificity of baseline subjective wellbeing cut-offs for cluster affiliation.
METHODS: Data was collected in an observational 36-month follow-up study of 2842 patients with schizophrenia in Germany. Subjective wellbeing was assessed using the SWN-K scale. Cluster analyses were applied based on Ward's procedure. Predictors were analyzed using logistic regression models. Optimal SWN-K total score cut-off points for cluster affiliation were analyzed using Cohen's kappa.
RESULTS: 4 distinct clusters were identified: a stable low (33%), a stable moderate (31%), a stable high (16%), and a cluster with distinct initial improvement and then stable high subjective wellbeing (20%). Highly concordant patterns were also observed for symptoms, social functioning, and quality of life. Sensitivity and specificity of SWN-K total score cut-offs at baseline were 82.8% and 63.8% for <or=60 points for the stable low cluster and 84.7% and 95.4% for >or=80 points for the stable high cluster. Affiliation to the stable low cluster was related to a 0.6% chance of being in recovery at 3-year endpoint.
CONCLUSIONS: Long-term patterns of subjective wellbeing are stable and highly concordant with course of symptoms, functioning level, and quality of life. Baseline subjective wellbeing cut-off points were found to be sufficient predictors of outcome, which, particularly in case of impaired subjective wellbeing and low baseline functioning level, make early treatment adaptations mandatory.

Entities:  

Mesh:

Year:  2008        PMID: 18842393     DOI: 10.1016/j.schres.2008.08.035

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.

Authors:  Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer
Journal:  BMC Psychiatry       Date:  2018-06-28       Impact factor: 3.630

2.  Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors.

Authors:  Michael S Ritsner; Alexander Lisker; Marina Arbitman
Journal:  Qual Life Res       Date:  2011-09-13       Impact factor: 4.147

3.  The mediating role of self-stigma and unmet needs on the recovery of people with schizophrenia living in the community.

Authors:  Kevin K S Chan; Winnie W S Mak
Journal:  Qual Life Res       Date:  2014-04-23       Impact factor: 4.147

Review 4.  [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

Authors:  L Deutschenbaur; M Lambert; M Walter; D Naber; C G Huber
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

5.  An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings: The PsyCourse Study.

Authors:  Dominic B Dwyer; Janos L Kalman; Monika Budde; Joseph Kambeitz; Anne Ruef; Linda A Antonucci; Lana Kambeitz-Ilankovic; Alkomiet Hasan; Ivan Kondofersky; Heike Anderson-Schmidt; Katrin Gade; Daniela Reich-Erkelenz; Kristina Adorjan; Fanny Senner; Sabrina Schaupp; Till F M Andlauer; Ashley L Comes; Eva C Schulte; Farah Klöhn-Saghatolislam; Anna Gryaznova; Maria Hake; Kim Bartholdi; Laura Flatau-Nagel; Markus Reitt; Silke Quast; Sophia Stegmaier; Milena Meyers; Barbara Emons; Ida Sybille Haußleiter; Georg Juckel; Vanessa Nieratschker; Udo Dannlowski; Tomoya Yoshida; Max Schmauß; Jörg Zimmermann; Jens Reimer; Jens Wiltfang; Eva Reininghaus; Ion-George Anghelescu; Volker Arolt; Bernhard T Baune; Carsten Konrad; Andreas Thiel; Andreas J Fallgatter; Christian Figge; Martin von Hagen; Manfred Koller; Fabian U Lang; Moritz E Wigand; Thomas Becker; Markus Jäger; Detlef E Dietrich; Harald Scherk; Carsten Spitzer; Here Folkerts; Stephanie H Witt; Franziska Degenhardt; Andreas J Forstner; Marcella Rietschel; Markus M Nöthen; Nikola Mueller; Sergi Papiol; Urs Heilbronner; Peter Falkai; Thomas G Schulze; Nikolaos Koutsouleris
Journal:  JAMA Psychiatry       Date:  2020-05-01       Impact factor: 21.596

6.  Do patterns of change during treatment for panic disorder predict future panic symptoms?

Authors:  Shari A Steinman; Michael D Hunter; Bethany A Teachman
Journal:  J Behav Ther Exp Psychiatry       Date:  2012-09-23

Review 7.  Schizophrenia outcomes in the 21st century: A systematic review.

Authors:  Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner
Journal:  Brain Behav       Date:  2021-05-15       Impact factor: 2.708

Review 8.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

9.  Health-related quality of life and overall life satisfaction in people with serious mental illness.

Authors:  Amy L Barnes; Meghan E Murphy; Christopher A Fowler; Melisa V Rempfer
Journal:  Schizophr Res Treatment       Date:  2012-11-19

10.  Satisfaction with Life of Schizophrenia Outpatients and Their Caregivers: Differences between Patients with and without Self-Reported Sleep Complaints.

Authors:  Sofia Brissos; Pedro Afonso; Fernando Cañas; Julio Bobes; Ivan Bernardo Fernandez; Carlos Guzman
Journal:  Schizophr Res Treatment       Date:  2013-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.